Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial

INTRODUCTION: Prior to investing in a large, multicentre randomised controlled trial (RCT), the National Institute for Health Research in the UK called for an evaluation of the feasibility and value for money of undertaking a trial on intravenous immunoglobulin (IVIG) as an adjuvant therapy for seve...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Crit Care
Hlavní autoři: Soares, Marta O, Welton, Nicky J, Harrison, David A, Peura, Piia, Shankar-Hari, Manu, Harvey, Sheila E, Madan, Jason, Ades, Anthony E, Rowan, Kathryn M, Palmer, Stephen J
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2014
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4271457/
https://ncbi.nlm.nih.gov/pubmed/25434816
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13054-014-0649-z
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky